Boston Microfluidics Appoints Linh Hoang, MD, PhD as CEO

CAMBRIDGE, Mass., June 8, 2020 – Boston Microfluidics (BMF), a developer of simple, intuitive blood collection devices, today announced that it has appointed Linh Hoang, MD, PhD, as its new Chief Executive Officer. In his new role, Dr. Hoang will oversee the company’s strategic growth and commercialization efforts of BMF’s products and services. Founder Brandon Johnson has been appointed Chief Innovation Officer of the company.

“The proprietary technology behind BMF’s core products is truly unmatched and will have a tremendous impact on the clinical diagnostics industry and telemedicine,” said Dr. Hoang. “Laboratory diagnostics inform a majority of medical decisions, and now more than ever, blood collection must evolve to enable at-home solutions. I am grateful for the opportunity to help lead this company into the next stage of its growth to bring BMF’s products to new markets and to the consumers that need them.”

Prior to joining BMF, Dr. Hoang was the Vice President of Reproductive Health at PerkinElmer and oversaw the prenatal and neonatal businesses, part of the clinical diagnostics segment. Prior to PerkinElmer, he led the Clinical Quality Controls business at Thermo Fisher Scientific.

BMF is currently working with industry partners to develop a serologic SARS-Cov-2 solution, using BMF’s proprietary collection device, that will allow consumers to easily collect a blood sample at home and mail it to a centralized laboratory for analysis. In contrast to virology testing which looks for active virus, serologic testing looks for antibodies in the bloodstream, indicating a possible immune response to the virus that could help the body to fight off another infection. Because serology tests require blood, the test is typically done with a phlebotomist at a centralized collection center. Options such as BMF’s collection device (in development) enables at-home collection which is a critical piece to ramping up serology testing.

“Despite the milestones the United States and other countries have achieved with increasing SARS-Cov-2 testing capacities, more testing is needed to better understand the virus and to know where it is spreading in real-time,” said Dr. Hoang. “By developing an at-home serologic test, BMF can help fill this significant testing gap, while providing people with a test that doesn’t require a visit to a doctor’s office or blood draw center – they can get a test without ever leaving their homes.”

BMF’s collection device was recently used to collect whole blood microsamples for the article, “Empiricism in Microsampling: Utilizing a Novel Lateral Flow Device and Intrinsic Normalization to Provide Accurate and Precise Clinical Analysis from a Finger Stick,” printed in Volume 66, Issue 6, of Clinical Chemistry (June 2020). The study demonstrates equivalency in analytical performance between venous blood draw and finger prick blood collection, which is enabled by the BMF’s device.

For more information about Boston Microfluidics and its products, please visit https://www.bostonmicrofluidics.com.

###

About Boston Microfluidics
Boston Microfluidics develops simple, intuitive, and needle-free blood collection devices designed to greatly simplify and revolutionize blood testing globally. Its mission is to design devices that make it easier for people, and their healthcare providers, to connect to their health, while reducing the barriers that prevent people from getting blood tests. For more information, please visit https://www.bostonmicrofluidics.com.

Boston Microfluidics Raises $17.5M in Series A Funding Round

CAMBRIDGE, Mass., August 27, 2019 – Boston Microfluidics (BMF), a developer of simple, intuitive blood collection devices, today announced it has raised $17.5 million in new funding. The Series A round was led by venture capital firm Anzu Partners and included leading global life sciences company (LabCorp Holdings). The funding will be used to bolster the company’s research and development efforts to continue improving BMF’s existing product line, and to develop new collection devices that make it easier for people, and their healthcare providers, to connect to their health.

“The majority of today’s blood collection for medical testing is done by phlebotomists or other trained medical personnel, using equipment that is not intended for use by consumers to collect their own specimens,” said Brandon Johnson, CEO of Boston Microfluidics. “BMF simplifies this process and brings healthcare to the consumer for an expanding menu of tests that can be done on these self-collected specimens. Working with our partners, we offer collection devices that can be used at home, making it easier for people to gain access to tests so that they can proactively monitor their health.”

“Using our device, consumers can simply prick their finger, place a few drops of blood into the device, close it, then drop it in the mail to the lab – all without leaving their home,” said Johnson. “And it only requires about five percent of the amount of blood compared to taking it from a person’s arm.”

Boston Microfluidics’ flagship product, the BMF Sample Collection Device, is the device used in the at-home collection kits offered through LabCorp’s consumer-initiated wellness testing platform, Pixel by LabCorp™. In addition to the at-home collection kits, Pixel by LabCorp offers certain laboratory testing for purchase to be collected at LabCorp’s patient service centers.

“LabCorp has been a great strategic partner to help us start getting our device into the hands of consumers,” said Johnson. “And that’s really just the beginning. We looking forward to expanding our base to reach more people around the world, and creating new products to make it easier for them to collect high quality samples.”

Boston Microfluidics is the first investment made by Anzu Partners’ second VC fund, which was announced in April 2019.

For more information about Boston Microfluidics, please visit https://www.bostonmicrofluidics.com.

###

About Boston Microfluidics
Boston Microfluidics develops simple, intuitive, and needle-free blood collection devices designed to greatly simplify and revolutionize blood testing globally. Its mission is to design devices that make it easier for people, and their healthcare providers, to connect to their health, while reducing the barriers that prevent people from getting blood tests. For more information, please visit https://www.bostonmicrofluidics.com.

About Anzu Partners
Anzu Partners is a venture capital and private equity firm that invests in breakthrough industrial technologies. Anzu teams with entrepreneurs to develop and commercialize technological innovations by providing capital and deep expertise in business development, market positioning, global connectivity, and operations. For more information, please visit https://anzupartners.com. On Twitter: @anzupartners.